Sun-grown. Community-owned. Seven years in the making.
Live - Open for investment The People's Plant (Ausmedicann P/L)
​Please consider the offer document and general risk warning before investing.
Retail investors are entitled to a 5 day cooling-off period.
Investments over $10,000 are restricted to Sophisticated investors - Apply here.
[wording around retail cap]
Click here to learn more about Equity Crowdfunding
An onshore answer to an imported problem
Ask where Australia’s medicinal cannabis comes from, and the honest answer is: much of it is imported.
For a medicine Australian patients rely on, we believe there is a better model - one that creates local jobs, reduces unnecessary transport and gives Australians greater control over a critical supply chain. A model built to serve patients for the long term, not simply the next sales quarter.
The People’s Plant® has taken a deliberate path to market. Over seven years of licensed research and development, we have bred and stabilised our own genetics, developed a sustainable cultivation method suited to our local Australian conditions, and designed our infrastructure around how we intend to grow at commercial scale.
That groundwork is now translating into commercial momentum. Our core cultivation infrastructure is complete, offtake agreements are in place, and nearly 2,500 Australians already own shares in the company.
With many of our major development milestones completed and a clear pathway towards commercial production, this campaign represents an opportunity to become a part-owner at a pivotal stage in our growth - before commercial production begins.
Investment highlights
- Seven years of licensed R&D completed and commercial production within reach
- A sustainable cultivation method we developed and proved ourselves, on-site
- Physical build complete - only the fit-out and security remain
- A clear, de-risked step from research into commercial production
- Offtake agreements and letters of intent already signed
- 100% onshore: Australian jobs and genuine supply security
- Close to 2,500 Australians already part-own the company
- An entry point set before revenue, at a clearly defined inflection point
How this raise moves us forward
We’ve built The People’s Plant® one funded milestone at a time, never getting ahead of ourselves. Earlier raises paid for the science and the structures - ongoing R&D, licence compliance, our genetics program, and the physical build: the greenhouse and protected cropping areas, a dedicated processing building, and a standalone irrigation facility.
This raise - our final before permit - funds the final stretch. With the physical build complete, the money goes straight into the processing fit-out and security, plus the compliance steps that make us production-ready.
Every round we’ve run has been pegged to a tangible build, never just a promise.
So this isn’t more of the same. It’s the step that turns seven years of groundwork into commercial supply, lets us deliver on the offtake interest already on the table, and opens the door for more Australians to share in what we’re building.
Two ways to generate revenue
The People’s Plant® runs on two revenue streams that feed each other: supplying other businesses (B2B), and building our own brand.
B2B comes first. Subject to our commercial permit, we’ll supply Australian-grown medicinal cannabis to licensed partners - wholesale, white-label and direct to pharmacy. Dried flower leads the range, with solventless extracts to follow. The demand is already there: offtake agreements and letters of intent are signed.
Our brand follows the demand we help create. Within the rules that govern cannabis marketing, we’ll focus on education, building awareness, and supporting the healthcare professionals who prescribe.
It all rests on one advantage: high-quality medicine grown affordably and sustainably. That means dependable local supply, a smaller environmental footprint, and far less reliance on imports.
To be clear, we’re not selling yet. Today the focus is finishing the fit-out and locking in regulatory readiness.
Built Differently from the Beginning
Most of Australia’s market runs on imported product and costly indoor growing. Many rushed to launch and locked themselves into high costs, leaving little room to compete on price, sustainability or scale.
We made the opposite bet. Seven years of licensed R&D went into a sustainable growing method tuned to our specific microclimate - one that can’t easily be copied elsewhere. Along the way we stabilised our genetics, learned our true cost of production, and engineered infrastructure for scale from the outset.
That head start is hard to buy. The time, regulatory complexity and upfront capital it demands have kept most competitors on the sidelines at this stage, so very few Australian producers are commercially ready with proven systems.
Add an all-onshore model, signed offtake agreements and a community of part owners behind us, and we’re well placed to start supplying as demand climbs.
It’s a chance to step in as a part owner at the turning point - before production starts and scale takes hold.
A growing market with a clear supply gap
Since legalisation in 2016, medicinal cannabis has gone mainstream in Australia. More than one million prescriptions have now been written, and approvals climb higher every year.
Yet the country still leans heavily on imports. Latest statistics show that in 2024, Australia brought in 77 tonnes of cannabis - up around 74% year-on-year - against just 42 tonnes grown locally. Demand is outpacing domestic supply almost two to one, leaving a clear opening for trusted, Australian-grown product.
Patients wear the cost of that gap. Many spend up to $1,000 a month - inflated by energy-hungry overseas indoor growing, freight and a long line of middlemen - with little say over quality, sustainability or price.
The environmental maths doesn’t help either: indoor cultivation emits far more per kilogram than greenhouse or outdoor growing, and that scrutiny is only sharpening.
Put it together and the opening is clear: a compliant local grower that can scale responsibly, beat imports on cost, and supply consistent, fresh, high-quality medicine into a market that keeps expanding.
Progress to date
- Australian medicinal cannabis cultivation licence in hand
- Seven years of licensed research and development completed
- Proprietary genetics bred and stabilised over multiple seasons
- Sustainable cultivation method validated through on-site trials
- Greenhouse and protected cropping infrastructure built
- Processing facility construction completed, sized for scale
- Offtake agreements and letters of intent signed pre-launch
- Three CSF raises completed - each funding a real build
- Close to 2,500 part owners, and still growing
Exclusive investor rewards
Owning a piece of The People’s Plant® comes with more than shares. Depending on how much you invest, you can unlock a tiered set of exclusive rewards - our way of thanking the community making this happen.
The Team
Ben Risby-Jones
Co-Founder & Managing Director
Rebecca Risby-Jones
Co-Founder & Director
Tim Joseph Hennessy
Co-Founder & Director
Terms of the Offer
Issued Capital
For more detailed information, please read the Capital Structure section of the offer document.
Use of Funds
For more information, please read the Use of Funds section of the offer document.
Company Risk
Ausmedicann Pty Ltd trading as The People’s Plant® Co is an Australian-owned medicinal cannabis company transitioning from seven years of licensed R&D into commercialisation. As with any growth business, an investment in the Company should be seen as high-risk and speculative. A description of the main risks that may impact their business are listed in the offer document. Investors should read this section carefully before deciding to apply for shares under the Offer. There are also other, more general, risks associated with the Company (for example, regulatory or permitting risk, funding and liquidity, execution and commercialisation, market demand and pricing, competition, operational and key personal, agricultural and environmental, related party, dilution, liquidity and exit, or the inability to sell their shares). See the Risk section in the Offer Document for further information.
The Offer is subject to a Maximum Subscription amount of $2,000,000. If the Maximum Subscription is reached, the Offer will close early. Applications will be treated on a time priority basis and may be subject to scale back, so please fund your application as soon as possible.
RISK WARNING: Crowd-sourced funding is risky. Issuers using this facility include new or rapidly growing ventures. Investment in these types of ventures is speculative and carries high risks. You may lose your entire investment, and you should be in a position to bear this risk without undue hardship. Even if the company is successful, the value of your investment and any return on the investment could be reduced if the company issues more shares. Your investment is unlikely to be liquid. This means you are unlikely to be able to sell your shares quickly or at all if you need the money or decide that this investment is not right for you.
Even though you have remedies for misleading statements in the replacement offer document or misconduct by the company, you may have difficulty recovering your money. There are rules for handling your money. However, if your money is handled inappropriately or the person operating this platform becomes insolvent, you may have difficulty recovering your money. Ask questions, read all information given carefully, and seek independent financial advice before committing yourself to any investment.
5 DAY COOLING OFF PERIOD: There is a 5 business day cooling off period for retail investors. During this period, you may withdraw your application and receive a full refund into your nominated refund account. Please note: After the 5 day cooling off period has expired, you will be unable to withdraw your application. More information here.
ONMARKET FEES: Upon successful completion of the Offer, a maximum fee of 6.5% of the funds raised will be paid to OnMarket by the Company.
ONMARKET INTERESTS: OnMarket and its associates may be participating in this offer.
ONMARKET INTERESTS AND AMOUNTS SUBJECT TO COOLING OFF: The funding bar displayed under each crowd funding offer may include applications where payments are yet to be made and amounts that are subject to the cooling off period.
Section 734(6) disclosure: The issuer of the securities is Ausmedicann Pty Ltd T/a The People's Plant ACN 632 788 133. The securities to be issued are fully-paid ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above)
Question time
We'd love to answer your questions, we'll have one of the OnMarket team or the company representative of the offer get back to you asap. So ask away ...
Can you please send me a copy of the offer documents?
Sarah M (OnMarket member) on 18/09/2026Please sign in to post a question